[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07717840":3,"trial-entities:NCT07717840":153,"trial-summary:NCT07717840":157},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":26,"interventions":29,"primary_outcomes":45,"secondary_outcomes":67,"sex":68,"minimum_age":69,"maximum_age":70,"healthy_volunteers":71,"eligibility_criteria":72,"std_ages":97,"locations":100,"central_contacts":144,"overall_officials":150,"references":151,"see_also_links":152},"NCT07717840","D7280C00001","A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)","A Phase I\u002FII, Randomized, Double-Blind, Active-Controlled Study to Characterize the Safety and Immunogenicity of AZD6489 in Adults 60 Years of Age and Older","RECRUITING","2027-09-06","2026-07","2026-07-21","2026-07-08","AstraZeneca","INDUSTRY",false,"This Phase I\u002FII study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.","This Phase I\u002FII clinical study will be conducted in the US at approximately 5 sites. The study is a randomized, double-blind, active-controlled study to characterize the safety and immunogenicity of a single dose of AZD6489 in adults ≥ 60 years of age. Two dose levels of AZD6489 will be assessed.\n\nApproximately 160 participants will be randomized and stratified by age group and previous receipt of RSV vaccine. Participants will be randomized\u002Fdosed to receive AZD6489, licensed RSV vaccine #1, or licensed RSV vaccine #2. The study is split into 2 cohorts based on the 2 dose levels of AZD6489 being studied.\n\nFor each cohort, an initial sentinel group of 8 participants will be followed up for safety via a telephone or teleconference call, approximately 48 hours post-study intervention, and the safety data will be evaluated by the SRC in order to provide a recommendation to continue randomization and vaccination for the remaining participants in that cohort.\n\nAn ESDR of all available safety data through 7 days post-vaccination of Cohort 1 will be conducted. Randomization of Cohort 2 will be allowed only after the ESDR of Cohort 1 participants has been completed and the results support that the safety profile is acceptable.\n\nThis study includes 5 in-clinic study visits. The duration of each participant's involvement in the study will be approximately 12 months following the administration of study intervention. Safety will be assessed for the duration of the study. Blood will be taken for immunological and safety assessments as per SoA.",[19],"RSV Respiratory Syncytial Virus",[],"INTERVENTIONAL","PREVENTION",[24,25],"PHASE1","PHASE2",{"count":27,"type":28},160,"ESTIMATED",[30,37,41],{"type":31,"name":32,"description":33,"armGroupLabels":34},"BIOLOGICAL","AZD6489","Participants will receive AZD6489 as a single intramuscular injection.",[35,36],"AZD6489 Dose A","AZD6489 Dose B",{"type":31,"name":38,"description":39,"armGroupLabels":40},"Licensed RSV vaccine #1","Participants will receive licensed RSV vaccine #1 as a single intramuscular injection.",[38],{"type":31,"name":42,"description":43,"armGroupLabels":44},"Licensed RSV vaccine #2","Participants will receive licensed RSV vaccine #2 as a single intramuscular injection.",[42],[46,50,53,56,59,61,63],{"measure":47,"description":48,"timeFrame":49},"Incidence of immediate unsolicited adverse events (AEs)","To assess the safety of a single IM vaccination with AZD6489 or licensed RSV vaccines","30 minutes post-study intervention",{"measure":51,"description":48,"timeFrame":52},"Incidence of injection site and systemic solicited adverse reactions (ARs)","Day 1 through 7 days post-study intervention",{"measure":54,"description":48,"timeFrame":55},"Incidence of unsolicited adverse events (AEs)","Day 1 through 28 days post-study intervention",{"measure":57,"description":48,"timeFrame":58},"Incidence of serious adverse events (SAEs)","Day 1 to Day 365",{"measure":60,"description":48,"timeFrame":58},"Incidence of adverse events of special interest (AESIs)",{"measure":62,"description":48,"timeFrame":58},"Incidence of medically attended adverse events (MAAEs)",{"measure":64,"description":65,"timeFrame":66},"RSV A nAb responses to AZD6489","To characterize the nAb responses to RSV A in serum following a single IM vaccination with AZD6489","Day 29",[],"ALL","60 Years",null,true,{"inclusion":73,"exclusion":78,"raw_text":96},[74,75,76,77],"Participant must be ≥ 60 years of age at the time of signing the informed consent.","Participants who are medically stable in the opinion of the Investigator at the time of study intervention. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension, or cardiac disease, are allowed to participate in this study if considered by the Investigator as medically stable.","Able to understand and comply with study requirements\u002Fprocedures including attending all scheduled study visits (if applicable, with assistance by caregiver, surrogate, or legally authorized representative or equivalent representative as locally defined) based on the assessment of the Investigator.","Capable of giving signed informed consent as described in Appendix A 3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.",[79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95],"Previous known laboratory-confirmed RSV infection within 6 months of Visit 1.","Moderate to severe acute (time-limited) or any febrile (temperature ≥ 38.0 °C \\[100.4 ºF\\]) illness\u002Finfection within 3 days of Visit 1; participants excluded for transient acute illness may be rescreened once and vaccinated if the illness has resolved.","History of a clinically significant bleeding disorder contraindicating IM injections or venipuncture based on Investigator judgment.","History of hypersensitivity to any component of the study interventions.","History of severe adverse reaction or severe allergic reaction (eg, anaphylaxis) associated with any vaccine.","Known chronic hepatitis B or C.","Known or suspected congenital or acquired immunodeficiency.","History of Guillain-Barré syndrome or any other demyelinating condition.","Current or previous (within the past 5 years) history of any malignancy (except treated non-melanoma skin cancers, locally treated cervical cancer, or prostate cancer that is stable at the time of vaccination in the absence of therapy).","Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion.","Receipt of any licensed or investigational RSV vaccine within 2 years prior to Visit 1, or planned receipt during the study.","Receipt of any licensed vaccine (including licensed influenza or COVID-19 vaccines) within 28 days prior to Visit 1 or expected receipt prior to end of Visit 3 assessments.","Receipt of immunoglobulin or blood products within 3 months prior to Visit 1, or planned receipt during the study.","Receipt of immune-modifying drugs or immunosuppressive therapy (eg, anti-cancer chemotherapy, anti-cytokine therapy, or radiation therapy) within 6 months prior to Visit 1, or planned receipt during study.","Long-term systemic corticosteroid therapy (prednisone or equivalent at a dose of ≥ 20 mg daily or every other day for more than 2 consecutive weeks) within 6 months prior to Visit 1 or planned receipt during study. Topical\u002Finhaled\u002Fintra-articular\u002Fophthalmic\u002Fotic steroids or short-term oral steroids are permitted.","Receipt of allergen immunotherapy if dose has been escalated or reduced within 30 days of Visit 1. Allergen immunotherapy is allowed if participant is receiving stable desensitization therapy for at least 30 days prior to Visit 1 and there is no anticipated change before Visit 3.","Participation in another clinical study with a study intervention administered in the preceding 90 days (or preceding 6 months for extended half-life drug products) or expected receipt of another study intervention during the study, or concurrent participation in another interventional study. Individuals who are in a prolonged post-administration observation period of another investigational, marketed drug, or non-interventional clinical study, for which there is no ongoing exposure to the investigational or marketed product and all scheduled on-site visits are completed, will be allowed to take part in this study, if all other eligibility criteria are met.","Inclusion Criteria:\n\n* Participant must be ≥ 60 years of age at the time of signing the informed consent.\n* Participants who are medically stable in the opinion of the Investigator at the time of study intervention. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension, or cardiac disease, are allowed to participate in this study if considered by the Investigator as medically stable.\n* Able to understand and comply with study requirements\u002Fprocedures including attending all scheduled study visits (if applicable, with assistance by caregiver, surrogate, or legally authorized representative or equivalent representative as locally defined) based on the assessment of the Investigator.\n* Capable of giving signed informed consent as described in Appendix A 3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\nExclusion Criteria:\n\n* Previous known laboratory-confirmed RSV infection within 6 months of Visit 1.\n* Moderate to severe acute (time-limited) or any febrile (temperature ≥ 38.0 °C \\[100.4 ºF\\]) illness\u002Finfection within 3 days of Visit 1; participants excluded for transient acute illness may be rescreened once and vaccinated if the illness has resolved.\n* History of a clinically significant bleeding disorder contraindicating IM injections or venipuncture based on Investigator judgment.\n* History of hypersensitivity to any component of the study interventions.\n* History of severe adverse reaction or severe allergic reaction (eg, anaphylaxis) associated with any vaccine.\n* Known chronic hepatitis B or C.\n* Known or suspected congenital or acquired immunodeficiency.\n* History of Guillain-Barré syndrome or any other demyelinating condition.\n* Current or previous (within the past 5 years) history of any malignancy (except treated non-melanoma skin cancers, locally treated cervical cancer, or prostate cancer that is stable at the time of vaccination in the absence of therapy).\n* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion.\n* Receipt of any licensed or investigational RSV vaccine within 2 years prior to Visit 1, or planned receipt during the study.\n* Receipt of any licensed vaccine (including licensed influenza or COVID-19 vaccines) within 28 days prior to Visit 1 or expected receipt prior to end of Visit 3 assessments.\n* Receipt of immunoglobulin or blood products within 3 months prior to Visit 1, or planned receipt during the study.\n* Receipt of immune-modifying drugs or immunosuppressive therapy (eg, anti-cancer chemotherapy, anti-cytokine therapy, or radiation therapy) within 6 months prior to Visit 1, or planned receipt during study.\n* Long-term systemic corticosteroid therapy (prednisone or equivalent at a dose of ≥ 20 mg daily or every other day for more than 2 consecutive weeks) within 6 months prior to Visit 1 or planned receipt during study. Topical\u002Finhaled\u002Fintra-articular\u002Fophthalmic\u002Fotic steroids or short-term oral steroids are permitted.\n* Receipt of allergen immunotherapy if dose has been escalated or reduced within 30 days of Visit 1. Allergen immunotherapy is allowed if participant is receiving stable desensitization therapy for at least 30 days prior to Visit 1 and there is no anticipated change before Visit 3.\n* Participation in another clinical study with a study intervention administered in the preceding 90 days (or preceding 6 months for extended half-life drug products) or expected receipt of another study intervention during the study, or concurrent participation in another interventional study. Individuals who are in a prolonged post-administration observation period of another investigational, marketed drug, or non-interventional clinical study, for which there is no ongoing exposure to the investigational or marketed product and all scheduled on-site visits are completed, will be allowed to take part in this study, if all other eligibility criteria are met.",[98,99],"ADULT","OLDER_ADULT",[101,110,116,123,130,137],{"facility":102,"status":8,"city":103,"state":104,"zip":105,"country":106,"geoPoint":107},"Research Site","Long Beach","California","90815","United States",{"lat":108,"lon":109},33.76696,-118.18923,{"facility":102,"status":8,"city":111,"state":104,"zip":112,"country":106,"geoPoint":113},"Rolling Hills Estates","90274",{"lat":114,"lon":115},33.78779,-118.35813,{"facility":102,"status":8,"city":117,"state":118,"zip":119,"country":106,"geoPoint":120},"Chicago","Illinois","60640",{"lat":121,"lon":122},41.85003,-87.65005,{"facility":102,"status":8,"city":124,"state":125,"zip":126,"country":106,"geoPoint":127},"Lenexa","Kansas","66219",{"lat":128,"lon":129},38.95362,-94.73357,{"facility":102,"status":8,"city":131,"state":132,"zip":133,"country":106,"geoPoint":134},"Kansas City","Missouri","64114",{"lat":135,"lon":136},39.09973,-94.57857,{"facility":102,"status":8,"city":138,"state":139,"zip":140,"country":106,"geoPoint":141},"Omaha","Nebraska","68134",{"lat":142,"lon":143},41.25626,-95.94043,[145],{"name":146,"role":147,"phone":148,"email":149},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[],[],[],{"nct_id":4,"conditions":154,"biomarkers":156},[155],"Respiratory Syncytial Virus",[],{"nct_id":4,"found":71,"summary":158,"prompt_version":168},{"design":159,"status":160,"heading":161,"summary":162,"follow_up":163,"word_count":164,"commitments":165,"compensation":166,"drugs_mentioned":167},"This is a Phase I\u002FII, randomized, double-blind, active-controlled study. It will involve approximately 160 participants who will be randomly assigned to receive one of the study interventions.","completed","A Study of AZD6489 for RSV in Older Adults (ARIES)","This study, called ARIES, is looking at a new vaccine called AZD6489 for Respiratory Syncytial Virus (RSV) in people aged 60 and older. Researchers want to understand how safe AZD6489 is and how well it helps your body create protection against RSV. You might receive AZD6489 or one of two already approved RSV vaccines. The study will enroll about 160 participants. Success in this study means seeing how often people have side effects (adverse events) right after the injection, in the first week, and within the first month. This helps researchers understand the vaccine's safety profile.","Your safety will be monitored for immediate side effects (30 minutes post-injection), injection site and body-wide reactions (up to 7 days post-injection), and other side effects (up to 28 days post-injection).",96,"You will have 5 in-clinic study visits. Your safety will be checked through phone calls after 48 hours and through follow-up for up to 28 days after the injection.","Not stated in the trial record.",[32],"v2"]